

NOW ENROLLING:

The PALomino Pregnancy Observational Safety Study for women with phenylketonuria (PKU) treated with Palynziq® (pegvaliase)

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

PALomino is a global observational safety study sponsored by BioMarin Pharmaceutical Inc. to assess maternal, fetal, and infant outcomes in women exposed to Palynziq® (pegvaliase) during pregnancy and breastfeeding.

Consider joining this pregnancy observational safety study to help doctors learn more about women taking Palynziq® during pregnancy. A pregnancy observational safety study collects health information about women who take prescription medicines when they are pregnant. These studies also collect information about the baby.

 What is the purpose of the PALomino Pregnancy Observational Safety Study?

This study will help doctors learn more about the safety of using Palynziq® during pregnancy and breastfeeding.

 Who can take part in the PALomino Pregnancy Observational Safety Study?

You may qualify for the study if you have taken Palynziq® at any time during your pregnancy.

What can I expect if I decide to participate?

There are no additional healthcare provider visits, testing, or treatments beyond the regular medical care you receive from your healthcare provider(s). With your consent, your healthcare provider(s) and your baby's healthcare provider(s) will be contacted to obtain information at various times about you, your pregnancy, and your baby through their first year of life. If you are breastfeeding, information about your Palynziq® prescription will be collected for up to 12 months after your baby is born. We will also collect information about your experience with Palynziq® and any potential side effects. There is no cost for you to take part in the study.

Ask your doctor if you qualify to participate in this observational safety study.

For more information, visit palominostudy.com or contact 833-672-2203.

